Bioregulators & Organ Support
Vilon
← Back to Library
Protocol not independently verified Immunity Bioregulator
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or human-trial protocol above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 20 mg
Dosing window: Anytime
Receptor / target: Thymus
Properties: Not stated
Pre-mixed: No
Protocol examples
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-10 | 10mg daily | Standard Khavinson protocol. Repeat every 6 months. |
Protocol example from the source dataset; verify against the evidence status and listed sources.
Alternative Titration 1: 5-Day Monthly Cycle Gradual Titration (Goal: sustained year-round immune maintenance; first-time users or subjects sensitive to immune activation)
| Timeframe | Dose | Notes |
|---|---|---|
| Month 1, Day 1 | 67 mcg 1x Daily | Gradual ramp: introduce thymopoietic signaling slowly to minimize first-cycle immune activation symptoms. |
| Month 1, Day 2 | 133 mcg 1x Daily | |
| Month 1, Day 3 | 200 mcg 1x Daily | |
| Month 1, Day 4 | 267 mcg 1x Daily | |
| Month 1, Day 5 | 333 mcg 1x Daily | |
| Month 2+, Day 1 | 333 mcg 1x Daily | Continue escalation each month until reaching 600 mcg cap. |
| Month 2+, Day 2 | 400 mcg 1x Daily | |
| Month 2+, Day 3 | 467 mcg 1x Daily | |
| Month 2+, Day 4 | 533 mcg 1x Daily | |
| Month 2+, Day 5 | 600 mcg 1x Daily |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Alternative Titration 2: 10-Day Quarterly Cycle (Goal: general immunosenescence reversal and aging immune normalization on a quarterly schedule)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-10 | 5mg 1x Daily | Half-dose intensive. Repeat every 3 months. |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Alternative Titration 3: Pre-Vaccination Immune Priming (Goal: maximize vaccine immunogenicity in aging or immunosenescent subjects by restoring naive T-cell output before antigen exposure)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-10 (4 weeks before vaccination) | 10mg 1x Daily | Full standard course 4 weeks before scheduled vaccination. Goal is to restore naive T-cell output and T-cell receptor repertoire breadth before novel antigen exposure. |
| Days 1-5 (1 week post-vaccination) | 5mg 1x Daily | Follow-up half-dose course to support the expanding antigen-specific T-cell response during the consolidation window. |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Alternative Titration 4: Post-Chemotherapy Immune Reconstruction (Goal: rebuild thymopoiesis and naive T-cell output following chemotherapy-induced lymphopenia; minimum 4 weeks post-chemotherapy, ANC > 1.0)
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 1mg 1x Daily | Ultra-conservative entry. Bone marrow recovery must be confirmed (ANC > 1.0) before initiating. Requires medical supervision. |
| Weeks 3-4 | 2mg 1x Daily | |
| Weeks 5-8 | 5mg 1x Daily | |
| Weeks 9-12 | 10mg 1x Daily | Full standard dose once T-cell recovery markers are trending toward normal range. |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Alternative Titration 5: Longevity Stack Integration with Epithalon + Crystagen (Goal: biannual deep immunosenescence reversal as part of comprehensive Khavinson anti-aging protocol)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-10 | 10mg 1x Daily | Run concurrently with Epithalon 10-day course. Stagger Crystagen to begin on Day 11 to avoid peak immune activation overlap. |
| Days 11-20 | 5mg 1x Daily | Vilon taper phase. Crystagen begins at its standard dose on Day 11. Provides sequential thymopoiesis restoration (Vilon) followed by broad peripheral immune normalization (Crystagen). |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Protocol logic check
Protocol context: Bioregulator protocols are often cycle-based because the claim is organ-system signaling rather than acute symptom control. The logic should be organ-specific labs, medical context, and humility about older or vendor-derived evidence. Entry context: target (Thymus); route Subcutaneous; timing Anytime. Unapproved or source-dataset dosing tables are hypotheses, not recommendations.
Independent evidence
Independent safety notes: No approved-label regimen was identified for this entry. Dosing examples should be treated as unverified protocol examples.
Regulatory status: no approved label identified
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Organ transplant recipients on immunosuppressive therapy: Vilon's T-cell restoration and thymopoietic stimulation directly counteracts the immunosuppressive regimens (calcineurin inhibitors, mTOR inhibitors, corticosteroids) required to prevent allograft rejection; restored T-cell activity increases the risk of acute and chronic rejection; absolute contraindication.
- Active autoimmune disease in acute flare: the immune normalization activity of Vilon, while not non-specific immunostimulation, could exacerbate the T-cell-mediated pathology driving active autoimmune flares in conditions such as rheumatoid arthritis, lupus, multiple sclerosis, or inflammatory bowel disease; use during active flare requires medical supervision.
- Concurrent immunosuppressive therapy for non-transplant indications (high-dose corticosteroids, methotrexate, azathioprine, biologic immunosuppressants): Vilon's immunoregulatory activity works against the therapeutic intent of these medications.
- Known hypersensitivity to Vilon (Lys-Glu dipeptide) or formulation excipients.
- Active hematological malignancies involving T-cell lineages (T-cell lymphoma, T-cell leukemia): Vilon's thymopoietic stimulation in the context of malignant T-cell clonal expansion could theoretically support tumor cell proliferation.
- Pregnancy: immune regulation changes substantially during pregnancy; exogenous thymic bioregulator activity during gestation is not characterized.
- Pediatric use in subjects with intact thymic function: the thymus is highly active in children and young adults; Vilon's therapeutic target (the involuted aging thymus) does not exist in young subjects and the effects of superimposed thymic bioregulator stimulation on normally functioning thymopoiesis are not established.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Transient immune activation symptoms: as T-cell output normalizes and immune competence is restored, some subjects experience mild flu-like symptoms (low-grade fatigue, mild myalgia) in the first days of a new cycle; reflects immune system reactivation rather than infection or adverse response.
- Mild injection site reaction: standard subcutaneous dipeptide injection response; minimal due to the small molecular size of Vilon.
- Transient mood changes: the neuroimmune cross-regulation between the thymus and the CNS/HPA axis means thymic bioregulator activity can produce subtle mood shifts in some subjects during the active cycle; typically mild and transient.
- Potential worsening of subclinical autoimmune conditions: immune normalization in subjects with undiagnosed autoimmune predisposition could unmask or mildly exacerbate previously subclinical autoimmune processes as immune surveillance and T-cell reactivity are restored.
- No serious adverse events documented in the Khavinson research literature: the 40+ year Russian clinical use history of Vilon at standard protocol doses has not produced documented serious adverse events; the safety profile is considered excellent in the eligible (aging, immunosenescent, non-transplant, non-active-autoimmune) population.
- Unknown interaction profile with modern biologic immunomodulatory drugs: Vilon's research predates the modern biologic immunotherapy era; interactions with checkpoint inhibitors, monoclonal antibodies, and targeted immunomodulators are not characterized.
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.